Caribou Biosciences to halt CAR-T programs, explore sale

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Caribou Biosciences to halt CAR-T programs, explore sale

Caribou Biosciences to Evaluate Strategic Alternatives

October 6, 2026 4:05 PM EDT

-- Company to evaluate strategic alternatives to maximize stockholder value --

-- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs --

-- Cash, cash equivalents, and marketable securities of $113.8 million as of June 30, 2026 --

BERKELEY, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development activities for its two... More